Should an abnormal serum potassium concentration be considered a correctable cause of cardiac arrest?
According to American Heart Association/American College of Cardiology Practice Guidelines, electrolyte abnormalities, including abnormal serum potassium concentrations, are considered a correctable cause of a life-threatening ventricular arrhythmia. Ventricular defibrillator therapy in this situation is a class III indication, and thought to be ineffective and perhaps harmful, although there are minimal data to support this recommendation. The steady-state serum potassium concentration frequently changes during a cardiac arrest. Additionally, the vast majority of cardiac arrest patients have structural heart disease and are commonly treated with a variety of medications that can alter the serum potassium concentration. In the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial, patients with a correctable cause of an electrolyte imbalance were excluded from study participation but were followed in the AVID registry. Similar outcomes were observed among patients in the AVID registry and the main trial. Spironolactone therapy in patients with congestive heart failure decreases all-cause mortality and sudden and nonsudden cardiac death. In a preliminary study of 169 patients with an episode of a sustained ventricular arrhythmia treated with an implantable defibrillator, freedom from appropriate defibrillator therapy was 18% after five years. The probability of appropriate defibrillator therapy was independent of the initial serum potassium concentration. For these reasons, our current clinical practice is to use an implantable defibrillator to treat an initial episode of sustained ventricular tachycardia or ventricular fibrillation that occurs in a patient with structural heart disease and an abnormal serum potassium concentration.